NLS Pharmaceutics AG (NLSP)
1.94
-0.09 (-4.43%)
At close: Jan 15, 2025, 3:59 PM
1.98
2.06%
After-hours Jan 15, 2025, 06:15 PM EST
Cashflow (Annual)
Get detailed ratio statement breakdowns, uncovering price to free cash flow ratio, price per earnings, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Net Income | -12.17M | -16.50M | -11.95M | -2.86M | -5.45M | -5.15M | -6.66M |
| Depreciation & Amortization | 11.41K | 11.41K | 10.05K | 72.19M | n/a | n/a | n/a |
| Stock-Based Compensation | 164.91K | 22.73K | n/a | n/a | n/a | n/a | 77.91 |
| Other Working Capital | -8.54K | 990.55K | -875.26K | 580.48K | 2.74M | 101.90K | -9.79K |
| Other Non-Cash Items | 59.53K | 364.64K | 166.51K | -72.12M | 1.14M | 1.75M | 884.31K |
| Deferred Income Tax | n/a | 613.42K | n/a | n/a | n/a | n/a | n/a |
| Change in Working Capital | 2.25M | 1.63M | -3.17M | 2.06M | 4.12M | 667.75K | 340.29K |
| Operating Cash Flow | -9.68M | -13.88M | -14.94M | -729.39K | -190.01K | -2.73M | -5.43M |
| Capital Expenditures | -4 | n/a | -39.56K | n/a | n/a | n/a | n/a |
| Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Investing Cash Flow | n/a | -3.51M | -39.56K | 225.64K | -217.25K | n/a | n/a |
| Debt Repayment | 1.63M | 825.84K | -2.10M | 1.19M | 154.89K | n/a | 3.45M |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | n/a | 7.35M | 7.89M | -686.70K | 252.59K | 557.92K | 3.28M |
| Financial Cash Flow | 1.63M | 17.40M | 20.34M | 503.52K | 407.48K | 557.92K | 6.73M |
| Net Cash Flow | -8.05M | 3.52M | 5.34M | -126.56K | 213.59K | -2.18M | 1.30M |
| Free Cash Flow | -9.68M | -13.88M | -14.98M | -729.39K | -190.01K | -2.73M | -5.43M |